Your browser doesn't support javascript.
loading
An alternative method of SNP inclusion to develop a generalized polygenic risk score analysis across Alzheimer's disease cohorts.
Brookes, Keeley J; Guetta-Baranes, Tamar; Thomas, Alan; Morgan, Kevin.
Afiliação
  • Brookes KJ; Interdisciplinary Biomedical Research Centre, Biosciences, Clifton Campus, Nottingham Trent University, Nottingham, United Kingdom.
  • Guetta-Baranes T; Human Genetics, Life Sciences, University Park, University of Nottingham, Nottingham, United Kingdom.
  • Thomas A; Brains for Dementia Research Coordinating Centre, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Morgan K; Human Genetics, Life Sciences, University Park, University of Nottingham, Nottingham, United Kingdom.
Front Dement ; 2: 1120206, 2023.
Article em En | MEDLINE | ID: mdl-39081983
ABSTRACT

Introduction:

Polygenic risk scores (PRSs) have great clinical potential for detecting late-onset diseases such as Alzheimer's disease (AD), allowing the identification of those most at risk years before the symptoms present. Although many studies use various and complicated machine learning algorithms to determine the best discriminatory values for PRSs, few studies look at the commonality of the Single Nucleotide Polymorphisms (SNPs) utilized in these models.

Methods:

This investigation focussed on identifying SNPs that tag blocks of linkage disequilibrium across the genome, allowing for a generalized PRS model across cohorts and genotyping panels. PRS modeling was conducted on five AD development cohorts, with the best discriminatory models exploring for a commonality of linkage disequilibrium clumps. Clumps that contributed to the discrimination of cases from controls that occurred in multiple cohorts were used to create a generalized model of PRS, which was then tested in the five development cohorts and three further AD cohorts.

Results:

The model developed provided a discriminability accuracy average of over 70% in multiple AD cohorts and included variants of several well-known AD risk genes.

Discussion:

A key element of devising a polygenic risk score that can be used in the clinical setting is one that has consistency in the SNPs that are used to calculate the score; this study demonstrates that using a model based on commonality of association findings rather than meta-analyses may prove useful.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article